vs
SANFILIPPO JOHN B & SON INC（JBSS）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
SANFILIPPO JOHN B & SON INC的季度营收约是REPLIGEN CORP的1.6倍（$314.8M vs $197.9M），REPLIGEN CORP净利率更高（6.7% vs 5.7%，领先1.0%），REPLIGEN CORP同比增速更快（13.6% vs 4.6%），SANFILIPPO JOHN B & SON INC自由现金流更多（$40.0M vs $17.6M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 7.6%）
John B. Sanfilippo & Son Inc.（股票代码JBSS）是美国领先的坚果零食加工分销商，主营树坚果、花生、果干及增值零食产品，为北美零售、餐饮及工业原料客户提供自有品牌和贴牌产品。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
JBSS vs RGEN — 直观对比
营收规模更大
JBSS
是对方的1.6倍
$197.9M
营收增速更快
RGEN
高出9.1%
4.6%
净利率更高
RGEN
高出1.0%
5.7%
自由现金流更多
JBSS
多$22.5M
$17.6M
两年增速更快
RGEN
近两年复合增速
7.6%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $314.8M | $197.9M |
| 净利润 | $18.0M | $13.3M |
| 毛利率 | 18.8% | 52.5% |
| 营业利润率 | 8.3% | 9.0% |
| 净利率 | 5.7% | 6.7% |
| 营收同比 | 4.6% | 13.6% |
| 净利润同比 | 32.1% | 143.9% |
| 每股收益（稀释后） | $1.53 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JBSSRGEN
| Q4 25 | $314.8M | $197.9M | ||
| Q3 25 | $298.7M | $188.8M | ||
| Q2 25 | $269.1M | $182.4M | ||
| Q1 25 | $260.9M | $169.2M | ||
| Q4 24 | $301.1M | $174.1M | ||
| Q3 24 | $276.2M | $154.9M | ||
| Q2 24 | $269.6M | $154.1M | ||
| Q1 24 | $271.9M | $151.3M |
净利润JBSSRGEN
| Q4 25 | $18.0M | $13.3M | ||
| Q3 25 | $18.7M | $14.9M | ||
| Q2 25 | $13.5M | $14.9M | ||
| Q1 25 | $20.2M | $5.8M | ||
| Q4 24 | $13.6M | $-30.3M | ||
| Q3 24 | $11.7M | $-654.0K | ||
| Q2 24 | $10.0M | $3.3M | ||
| Q1 24 | $13.5M | $2.1M |
毛利率JBSSRGEN
| Q4 25 | 18.8% | 52.5% | ||
| Q3 25 | 18.1% | 53.2% | ||
| Q2 25 | 18.1% | 50.0% | ||
| Q1 25 | 21.4% | 53.6% | ||
| Q4 24 | 17.4% | 26.1% | ||
| Q3 24 | 16.9% | 50.0% | ||
| Q2 24 | 18.5% | 49.8% | ||
| Q1 24 | 18.1% | 49.5% |
营业利润率JBSSRGEN
| Q4 25 | 8.3% | 9.0% | ||
| Q3 25 | 9.0% | 8.9% | ||
| Q2 25 | 7.5% | 7.6% | ||
| Q1 25 | 10.8% | 3.9% | ||
| Q4 24 | 6.4% | -17.7% | ||
| Q3 24 | 6.2% | -5.1% | ||
| Q2 24 | 5.4% | 1.0% | ||
| Q1 24 | 6.7% | 1.3% |
净利率JBSSRGEN
| Q4 25 | 5.7% | 6.7% | ||
| Q3 25 | 6.3% | 7.9% | ||
| Q2 25 | 5.0% | 8.2% | ||
| Q1 25 | 7.7% | 3.4% | ||
| Q4 24 | 4.5% | -17.4% | ||
| Q3 24 | 4.2% | -0.4% | ||
| Q2 24 | 3.7% | 2.2% | ||
| Q1 24 | 5.0% | 1.4% |
每股收益（稀释后）JBSSRGEN
| Q4 25 | $1.53 | $0.24 | ||
| Q3 25 | $1.59 | $0.26 | ||
| Q2 25 | $1.15 | $0.26 | ||
| Q1 25 | $1.72 | $0.10 | ||
| Q4 24 | $1.16 | $-0.55 | ||
| Q3 24 | $1.00 | $-0.01 | ||
| Q2 24 | $0.85 | $0.06 | ||
| Q1 24 | $1.15 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4M | $767.6M |
| 总债务越低越好 | $28.8M | $542.2M |
| 股东权益账面价值 | $370.1M | $2.1B |
| 总资产 | $617.7M | $2.9B |
| 负债/权益比越低杠杆越低 | 0.08× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资JBSSRGEN
| Q4 25 | $2.4M | $767.6M | ||
| Q3 25 | $714.0K | $748.7M | ||
| Q2 25 | $585.0K | $708.9M | ||
| Q1 25 | $1.3M | $697.2M | ||
| Q4 24 | $336.0K | $757.4M | ||
| Q3 24 | $442.0K | $784.0M | ||
| Q2 24 | $484.0K | $809.1M | ||
| Q1 24 | $377.0K | $780.6M |
总债务JBSSRGEN
| Q4 25 | $28.8M | $542.2M | ||
| Q3 25 | $29.8M | $537.9M | ||
| Q2 25 | $14.6M | — | ||
| Q1 25 | $5.8M | — | ||
| Q4 24 | $6.0M | $525.6M | ||
| Q3 24 | $6.2M | — | ||
| Q2 24 | $6.4M | — | ||
| Q1 24 | $6.6M | — |
股东权益JBSSRGEN
| Q4 25 | $370.1M | $2.1B | ||
| Q3 25 | $362.8M | $2.1B | ||
| Q2 25 | $360.7M | $2.1B | ||
| Q1 25 | $346.6M | $2.0B | ||
| Q4 24 | $325.6M | $2.0B | ||
| Q3 24 | $310.8M | $2.0B | ||
| Q2 24 | $322.6M | $2.0B | ||
| Q1 24 | $321.8M | $2.0B |
总资产JBSSRGEN
| Q4 25 | $617.7M | $2.9B | ||
| Q3 25 | $598.7M | $2.9B | ||
| Q2 25 | $597.6M | $2.9B | ||
| Q1 25 | $590.0M | $2.9B | ||
| Q4 24 | $545.3M | $2.8B | ||
| Q3 24 | $519.4M | $2.8B | ||
| Q2 24 | $515.6M | $2.9B | ||
| Q1 24 | $491.9M | $2.8B |
负债/权益比JBSSRGEN
| Q4 25 | 0.08× | 0.26× | ||
| Q3 25 | 0.08× | 0.26× | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | 0.02× | — | ||
| Q4 24 | 0.02× | 0.27× | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | 0.02× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $62.5M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $40.0M | $17.6M |
| 自由现金流率自由现金流/营收 | 12.7% | 8.9% |
| 资本支出强度资本支出/营收 | 7.1% | 4.1% |
| 现金转化率经营现金流/净利润 | 3.48× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $32.8M | $93.9M |
8季度趋势，按日历期对齐
经营现金流JBSSRGEN
| Q4 25 | $62.5M | $25.7M | ||
| Q3 25 | $32.1M | $48.1M | ||
| Q2 25 | $36.5M | $28.6M | ||
| Q1 25 | $-25.9M | $15.0M | ||
| Q4 24 | $11.0M | $39.2M | ||
| Q3 24 | $8.9M | $49.3M | ||
| Q2 24 | $35.2M | $42.2M | ||
| Q1 24 | $5.3M | $44.7M |
自由现金流JBSSRGEN
| Q4 25 | $40.0M | $17.6M | ||
| Q3 25 | $7.3M | $43.4M | ||
| Q2 25 | $23.0M | $21.5M | ||
| Q1 25 | $-37.6M | $11.4M | ||
| Q4 24 | $-2.7M | $33.6M | ||
| Q3 24 | $-3.0M | $42.3M | ||
| Q2 24 | $24.4M | $37.4M | ||
| Q1 24 | $-1.3M | $36.4M |
自由现金流率JBSSRGEN
| Q4 25 | 12.7% | 8.9% | ||
| Q3 25 | 2.4% | 23.0% | ||
| Q2 25 | 8.6% | 11.8% | ||
| Q1 25 | -14.4% | 6.8% | ||
| Q4 24 | -0.9% | 19.3% | ||
| Q3 24 | -1.1% | 27.3% | ||
| Q2 24 | 9.0% | 24.3% | ||
| Q1 24 | -0.5% | 24.0% |
资本支出强度JBSSRGEN
| Q4 25 | 7.1% | 4.1% | ||
| Q3 25 | 8.3% | 2.5% | ||
| Q2 25 | 5.0% | 3.9% | ||
| Q1 25 | 4.5% | 2.1% | ||
| Q4 24 | 4.5% | 3.2% | ||
| Q3 24 | 4.3% | 4.5% | ||
| Q2 24 | 4.0% | 3.1% | ||
| Q1 24 | 2.4% | 5.5% |
现金转化率JBSSRGEN
| Q4 25 | 3.48× | 1.93× | ||
| Q3 25 | 1.72× | 3.23× | ||
| Q2 25 | 2.70× | 1.92× | ||
| Q1 25 | -1.29× | 2.57× | ||
| Q4 24 | 0.81× | — | ||
| Q3 24 | 0.77× | — | ||
| Q2 24 | 3.52× | 12.70× | ||
| Q1 24 | 0.39× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JBSS
| Sales Channel Directly To Consumer | $263.2M | 84% |
| Sales Channel Commercial Ingredients | $28.0M | 9% |
| Sales Channel Contract Packaging | $23.6M | 8% |
RGEN
暂无分部数据
